Experimental drug aims to halt scarring hair loss
NCT ID NCT05549934
First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time
Summary
This pilot study tests an experimental drug called ritlecitinib in people with cicatricial alopecia, a type of hair loss where hair follicles are permanently destroyed and replaced by scar tissue. The drug works by blocking certain enzymes involved in inflammation. Researchers will check if the drug is safe and how it affects biomarkers in skin and blood samples from 50 adult participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ritlecitinib, a JAK3/TEC inhibitor taken as tablets
- What this could lead to
- If successful, this could point toward a treatment for cicatricial alopecia, a scarring hair loss condition with no effective therapies.
- What could go wrong
- This is a small, early-phase pilot study with only 50 participants, so results may not apply broadly. The drug may not show benefit or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CICATRICIAL ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.